Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Are These Four Stocks Making A Late Surge?

Page 1 of 2

Shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Novavax, Inc. (NASDAQ:NVAX), and Diamond Offshore Drilling Inc (NYSE:DO) are certainly happy today, as the value of their holdings in the stock are surging in afternoon trading thanks to various catalysts. Let’s find out why and examine what the smart money thinks of the four stocks.

Most Affordable Chemical Engineering Schools in The US

Most investors don’t understand hedge funds and indicators that are based on hedge funds’ activities. They ignore hedge funds because of their recent poor performance in the bull market. Our research indicates that hedge funds underperformed because they aren’t 100% long. Hedge fund fees are also very large compared to the returns generated and they reduce the net returns experienced by investors. We uncovered that hedge funds’ long positions actually outperformed the market. For instance the 15 most popular small-cap stocks among funds beat the S&P 500 Index by more than 52 percentage points since the end of August 2012. These stocks returned a cumulative of 102% vs. a 48.7% gain for the S&P 500 Index (see the details here). That’s why we believe investors should pay attention to what hedge funds are buying (rather than what their net returns are).

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is up by 12.9% as sentiment for the stock improves. Amicus’ stock tanked in October after the company said it will not file the NDA for migalastat for the treatment of Fabry disease this year after communicating with the FDA. The FDA wants more information, which will take time to complete. Despite the setback, Amicus has potential, as investors believe migalastat has better dosing superiority in 30%-to-50% of Fabry patients than current treatments such as Fabrazyme and Replagal. With $3.05 in cash per share, Amicus has enough money to keep the lights on for a while and finance any additional data the FDA needs.

According to our data culled from approximately 730 elite funds in our database, smart money investors were bullish on Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the second quarter. 31 funds reported stakes as of June 30 worth $687.19 million, accounting for 41.90% of the stock’s float, up from 26 funds and $520.91 million respectively at the end of March. Joseph Edelman‘s Perceptive Advisors owned 14.44 million shares at the end of the second quarter.

Follow Amicus Therapeutics Inc (NASDAQ:FOLD)
Trade (NASDAQ:FOLD) Now!

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has rallied by 15.3% after the FDA granted the company’s NDA for NUPLAZID priority review. ACADIA Pharmaceuticals is seeking FDA approval of NUPLAZID for the treatment of psychosis associated with Parkinsons disease. The market could be substantial, as one million Americans suffer from Parkinsons disease, with an estimated 40% experiencing Parkinsons-related psychosis. A priority review speeds up the review timeline to six months from ten months, and gives NUPLAZID a PDUFA date of May 1, 2016. Hedge funds were bullish on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in the second quarter. 26 funds reported owning ACADIA stakes worth $1.11 billion, holding 26.30% of all shares. Julian Baker and Felix Baker‘s Baker Bros. Advisors owned 20.48 million shares at the end of the second quarter.

Follow Acadia Pharmaceuticals Inc (NASDAQ:ACAD)
Trade (NASDAQ:ACAD) Now!

On the next page, we examine why Novavax and Diamond Offshore Drilling are rallying.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!